MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ
1.200
-0.030
-2.44%
After Hours: 1.180 -0.02 -1.67% 16:04 04/12 EDT
OPEN
1.210
PREV CLOSE
1.230
HIGH
1.240
LOW
1.180
VOLUME
3.75M
TURNOVER
0
52 WEEK HIGH
1.960
52 WEEK LOW
0.7120
MARKET CAP
210.45M
P/E (TTM)
-8.3218
1D
5D
1M
3M
1Y
5Y
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
NASDAQ · 1d ago
RIGEL PHARMACEUTICALS: ON APRIL 11, ENTERED AMENDMENT TO CREDIT & SECURITY DEAL OF SEPT 27, 2019 TO EXTEND MATURITY FOR TERM LOANS TO SEPT 1, 2027
Reuters · 1d ago
RIGEL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Weekly Report: what happened at RIGL last week (0401-0405)?
Weekly Report · 5d ago
Market Sentiment Around Loss-Making Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)
Rigel Pharmaceuticals, Inc. Announced a latest loss of US$25m for its most recent financial year. The company is expected to grow at an average annual rate of 55%. The company has negative equity on its balance sheet and is on the verge of becoming profitable. Rigel pharmaceuticals engages in discovering and developing therapies for hematologic disorders and cancer.
Simply Wall St · 04/04 13:33
Rigel Publishes Data On REZLIDHIA In Post-Venetoclax Patients With Mutant IDH1 AML In Leukemia & Lymphoma
Benzinga · 04/04 12:11
RIGEL PHARMACEUTICALS INC <RIGL.O>: JEFFERIES RAISES TARGET PRICE TO $1.65 FROM $1
Reuters · 04/02 04:40
Monday Sector Laggards: Biotechnology, Water Utilities
NASDAQ · 04/01 16:08
More
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.

Webull offers Rigel Pharmaceuticals Inc stock information, including NASDAQ: RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.